“`html
BioRestorative Therapies, Inc. will present preliminary safety and efficacy data from its Phase 2 trial of BRTX-100 for chronic lumbar disc disease (cLDD) at the International Society for Stem Cell Research (ISSCR) 2025 Annual Meeting in Hong Kong on June 13, 2025. The data, derived from a study involving 30 patients, will highlight improvements in safety and patient-reported outcomes. The presentation will be led by Francisco Silva, Vice President of Research and Development at BioRestorative.
The ongoing Phase 2 trial aims to enroll a total of 99 patients across 16 clinical sites, randomized to receive either BRTX-100 or a placebo. BioRestorative plans to publicly release this clinical data before market opening on the same day as the presentation.
“`
